ETC

Recommend
Index
  • VaxigripTetra

    VaxigripTetra

    Ingredient

    A/Victoria/2570/2019 (H1N1)pdm09 – like strain (A/Victoria/2570/2019, IVR-215)
    A/Hong Kong/2671/2019 (H3N2) – like strain (A/Hong Kong/2671/2019, IVR-208)
    B/Washington/02/2019 – like strain (B/Washington/02/2019, wild type)
    B/Phuket/3073/2013 – like strain (B/Phuket/3073/2013, wild type)

    Content
    Indication

    the prevention of influenza disease caused by the two influenza A virus
    subtypes and the two influenza B virus types contained in the vaccine for:
    – active immunisation of adults, including pregnant women, and children from 6 months of age.
    – passive protection of infants less than 6 months of age and born to women vaccinated during
    pregnancy

  • Viviant

    Viviant

    Ingredient

    bazedoxifene acetate

    Content

    bazedoxifene acetate(as bazedoxifene) 20mg

    Indication

    Treatment and prevention of osteoporosis in postmenopausal women.

    **However, this drug reduced the incidence of spinal fractures, but the effectiveness for non-spinal fractures has not been established.

  • Vyxeos liposomal inj.

    Vyxeos liposomal inj.

    Ingredient

    Each vial contains 44 mg of daunorubicin and 100 mg of cytarabine

    Content

    Powder for concentrate for solution for infusion.
    Purple, lyophilised cake.

    Indication

    Vyxeos liposomal is indicated for the treatment of adults with newly diagnosed, therapy-related acute
    myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)

TOP